| Year |
Citation |
Score |
| 2020 |
Zhang W, Sun H, Guh DP, Lynd LD, Hollis A, Grootendorst P, Anis AH. The Impact of Tiered-Pricing Framework on Generic Entry in Canada. International Journal of Health Policy and Management. PMID 33233033 DOI: 10.34172/ijhpm.2020.215 |
0.476 |
|
| 2020 |
Zhang W, Guh DP, Sun H, Lynd LD, Hollis A, Grootendorst P, Anis AH. Factors associated with drug shortages in Canada: a retrospective cohort study. Cmaj Open. 8: E535-E544. PMID 32873582 DOI: 10.9778/cmajo.20200036 |
0.474 |
|
| 2020 |
Kaal KJ, Bansback N, Hudson M, Anis A, Koehn C, Harrison M. Patient-provider communication about medication cost in rheumatoid arthritis. Clinical Rheumatology. PMID 32506315 DOI: 10.1007/S10067-020-05188-Z |
0.367 |
|
| 2019 |
Ling DI, Lynd LD, Harrison M, Anis AH, Bansback N. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. Journal of Comparative Effectiveness Research. 8: 7-19. PMID 30525982 DOI: 10.2217/Cer-2018-0033 |
0.485 |
|
| 2018 |
Atiquzzaman M, Kopec J, Karim ME, Wong H, Anis A. OP0190 The role of nsaids in the association between osteoarthritis and cardiovascular diseases: a population-based cohort study Annals of the Rheumatic Diseases. 77: 144-144. DOI: 10.1136/Annrheumdis-2018-Eular.2640 |
0.307 |
|
| 2017 |
Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, Anis A. Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. Cost Effectiveness and Resource Allocation : C/E. 15: 20. PMID 28904528 DOI: 10.1186/S12962-017-0081-8 |
0.323 |
|
| 2016 |
Zhang W, Guh D, Sun H, Marra CA, Lynd LD, Anis AH. The Impact of Price-Cap Regulations on Exit by Generic Pharmaceutical Firms. Medical Care. PMID 27213540 DOI: 10.1097/Mlr.0000000000000577 |
0.575 |
|
| 2016 |
Harvard S, Guh D, Bansback N, Richette P, Dougados M, Anis A, Fautrel B. Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort. Rmd Open. 2: e000230. PMID 27099778 DOI: 10.1136/Rmdopen-2015-000230 |
0.348 |
|
| 2015 |
Bansback N, Keystone E, O'Dell J, Phibbs CS, Hannagan K, Brophy M, Anis A. Making smart investment decisions in clinical research. Trials. 16: 590. PMID 26712327 DOI: 10.15272/Ajcr.V2016I1.3 |
0.302 |
|
| 2015 |
Sharif B, Kopec J, Bansback N, Rahman MM, Flanagan WM, Wong H, Fines P, Anis A. Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model. Osteoarthritis and Cartilage / Oars, Osteoarthritis Research Society. 23: 1654-63. PMID 26050868 DOI: 10.1016/J.Joca.2015.05.029 |
0.311 |
|
| 2015 |
Harvard S, Molto A, Guh D, Bansback N, Dougados M, Paternotte S, Richette P, Fautrel B, Anis A. FRI0369 Health Utilities and Costs Among Early Spondyloarthritis Patients Treated and not Treated with TNFα Blockers: Estimates from the Desir Cohort Annals of the Rheumatic Diseases. 74: 560.1-560. DOI: 10.1136/Annrheumdis-2015-Eular.3539 |
0.385 |
|
| 2015 |
Harvard S, Guh D, Bansback N, Richette P, Dougados M, Anis A, Fautrel B. THU0369 Costs of Early Spondyloarthritis: Estimates from the First Three Years of the Desir Cohort Annals of the Rheumatic Diseases. 74: 329.2-330. DOI: 10.1136/Annrheumdis-2015-Eular.3211 |
0.35 |
|
| 2013 |
Bansback N, Fu E, Sun H, Guh D, Anis A, Lacaille D. FRI0440 Trends in rheumatoid arthritis related resource utilization in british columbia, canada: A population based cohort study Annals of the Rheumatic Diseases. 71: 463.1-463. DOI: 10.1136/Annrheumdis-2012-Eular.2897 |
0.419 |
|
| 2012 |
Marra CA, Lynd LD, Colley L, Harvard SS, Lacaille D, Schwenger E, Anis AH, Esdaile JM. Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. The Journal of Rheumatology. 39: 910-5. PMID 22422500 DOI: 10.3899/Jrheum.110604 |
0.617 |
|
| 2012 |
Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. Plos One. 7: e31115. PMID 22328929 DOI: 10.1371/Journal.Pone.0031115 |
0.323 |
|
| 2012 |
Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 14: 520-6. PMID 22241089 DOI: 10.1038/Gim.2011.26 |
0.601 |
|
| 2012 |
Bansback N, Zhang W, Walsh D, Kiely P, Williams R, Guh D, Anis A, Young A. Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA. Rheumatology (Oxford, England). 51: 375-84. PMID 22179728 DOI: 10.1093/Rheumatology/Ker385 |
0.335 |
|
| 2011 |
Anis A, Harvard S, Marra C. Ontario's plunging price-caps on generics: deeper dives may drown some drugs. Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal. 5: e149-52. PMID 22046229 |
0.457 |
|
| 2011 |
Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F. Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 14: 937-43. PMID 21914516 DOI: 10.1016/J.Jval.2011.05.003 |
0.413 |
|
| 2011 |
Woolcott JC, Khan KM, Mitrovic S, Anis AH, Marra CA. The cost of fall related presentations to the ED: a prospective, in-person, patient-tracking analysis of health resource utilization. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 23: 1513-9. PMID 21892675 DOI: 10.1007/S00198-011-1764-1 |
0.464 |
|
| 2011 |
Marra CA, Bansback N, Anis AH, Shojania K. Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clinical Rheumatology. 30: S9-18. PMID 21359506 DOI: 10.1007/S10067-010-1635-8 |
0.544 |
|
| 2009 |
Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Annals of Internal Medicine. 151: 612-21. PMID 19884622 DOI: 10.7326/0003-4819-151-9-200911030-00006 |
0.504 |
|
| 2009 |
Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, Sato R. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford, England). 48: 1283-9. PMID 19690125 DOI: 10.1093/Rheumatology/Kep239 |
0.34 |
|
| 2009 |
Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology. 23: 83-92. PMID 19233048 DOI: 10.1016/J.Berh.2008.11.005 |
0.588 |
|
| 2009 |
Bansback N, Ara R, Ward S, Anis A, Choi HK. Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics. 27: 25-37. PMID 19178122 DOI: 10.2165/00019053-200927010-00004 |
0.38 |
|
| 2008 |
McTaggart-Cowan HM, Shi P, Fitzgerald JM, Anis AH, Kopec JA, Bai TR, Soon JA, Lynd LD. An evaluation of patients' willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experiment. The Journal of Asthma : Official Journal of the Association For the Care of Asthma. 45: 630-8. PMID 18951253 DOI: 10.1080/02770900802126990 |
0.477 |
|
| 2008 |
Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. The Journal of Rheumatology. 35: 1729-36. PMID 18688916 |
0.488 |
|
| 2008 |
Bansback NJ, Anis AH, Marra CA. Patient reported outcomes for rheumatoid arthritis: where are we and where are we going? The Journal of Rheumatology. 35: 1482-3. PMID 18671320 |
0.469 |
|
| 2008 |
Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A. Health state utility values: a description of their development and application for rheumatic diseases. Arthritis and Rheumatism. 59: 1018-26. PMID 18576311 DOI: 10.1002/Art.23813 |
0.567 |
|
| 2008 |
Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. Pharmacoeconomics. 26: 395-408. PMID 18429656 DOI: 10.2165/00019053-200826050-00004 |
0.399 |
|
| 2008 |
McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, FitzGerald JM, Anis AH, Lynd LD. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 17: 453-62. PMID 18274882 DOI: 10.1007/S11136-008-9309-6 |
0.592 |
|
| 2007 |
Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond T, Brazier J. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis and Rheumatism. 57: 963-71. PMID 17665482 DOI: 10.1002/Art.22885 |
0.566 |
|
| 2007 |
Bansback N, Maetzel A, Drummond M, Anis A, Marra C, Conway P, Boers M, Tugwell P, Boonen A. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. The Journal of Rheumatology. 34: 1178-83. PMID 17477483 |
0.491 |
|
| 2006 |
Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, Clarke AE, Gignac MA, Anis AH. Not all "quality-adjusted life years" are equal. Journal of Clinical Epidemiology. 60: 616-24. PMID 17493521 DOI: 10.1016/J.Jclinepi.2006.09.006 |
0.433 |
|
| 2006 |
Tan MC, Regier DA, Esdaile JM, Lynd LD, Anis AH, Marra CA. Health economic evaluation: a primer for the practicing rheumatologist. Arthritis and Rheumatism. 55: 648-56. PMID 16874788 DOI: 10.1002/Art.22105 |
0.601 |
|
| 2006 |
Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health and Quality of Life Outcomes. 4: 25. PMID 16626489 DOI: 10.1186/1477-7525-4-25 |
0.497 |
|
| 2006 |
Marra CA, Lynd LD, Anis AH, Esdaile JM. Approval process and access to prescription drugs in Canada. Arthritis and Rheumatism. 55: 9-11. PMID 16463404 DOI: 10.1002/Art.21709 |
0.569 |
|
| 2005 |
Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X, Esdaile JM. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 173: 1335-40. PMID 16301701 DOI: 10.1503/Cmaj.045146 |
0.521 |
|
| 2005 |
Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 14: 1333-44. PMID 16047508 DOI: 10.1007/S11136-004-6012-0 |
0.504 |
|
| 2005 |
De Civita M, Regier D, Alamgir AH, Anis AH, Fitzgerald MJ, Marra CA. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics. 23: 659-85. PMID 15987225 DOI: 10.2165/00019053-200523070-00003 |
0.465 |
|
| 2005 |
Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. Drugs. 65: 473-96. PMID 15733011 DOI: 10.2165/00003495-200565040-00004 |
0.548 |
|
| 2005 |
Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science & Medicine (1982). 60: 1571-82. PMID 15652688 DOI: 10.1016/J.Socscimed.2004.08.034 |
0.518 |
|
| 2005 |
Anis A, Guh D, Bansback N, Melilli L. UB4 DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS Value in Health. 8: A4-A5. DOI: 10.1016/S1098-3015(10)67154-9 |
0.354 |
|
| 2004 |
Marra CA, Esdaile JM, Guh D, Kopec JA, Brazier JE, Koehler BE, Chalmers A, Anis AH. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Medical Care. 42: 1125-31. PMID 15586840 DOI: 10.1097/00005650-200411000-00012 |
0.523 |
|
| 2004 |
Lynd LD, Sandford AJ, Kelly EM, Paré PD, Bai TR, FitzGerald JM, Anis AH. Reconcilable defferences: A cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting β-agonist use in asthma Chest. 126: 1161-1168. PMID 15486378 DOI: 10.1378/Chest.126.4.1161 |
0.466 |
|
| 2004 |
Lynd LD, Warren LD, Maclure M, Paré PD, Anis AH. Using administrative healthcare data to recruit study subjects: Experience with 'Camouflaged Sampling' European Journal of Epidemiology. 19: 517-525. PMID 15330123 DOI: 10.1023/B:Ejep.0000032369.60873.60 |
0.446 |
|
| 2004 |
Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology (Oxford, England). 43: 1390-7. PMID 15292531 DOI: 10.1093/Rheumatology/Keh334 |
0.634 |
|
| 2003 |
Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. The Annals of Pharmacotherapy. 37: 1256-65. PMID 12921510 DOI: 10.1345/Aph.1C039 |
0.465 |
|
| 2002 |
Lynd LD, Guh DP, Paré PD, Anis AH. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada. Chest. 122: 1973-81. PMID 12475835 DOI: 10.1378/Chest.122.6.1973 |
0.462 |
|
| 2002 |
Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. The Journal of Rheumatology. 29: 2507-12. PMID 12465143 |
0.446 |
|
| 2001 |
Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis and Rheumatism. 45: 240-5. PMID 11409664 DOI: 10.1002/1529-0131(200106)45:3<240::Aid-Art255>3.0.Co;2-I |
0.47 |
|
| 2001 |
Lynd L, Guh D, Pare P, Anis A. PAR3: THE STANDARDIZED ASTHMA-RELATED QUALITY OF LIFE QUESTIONNAIRE (AQLQ-S): DOES SOCIOECONOMIC STATUS EFFECT MEASUREMENTS? Value in Health. 4: 75-76. DOI: 10.1046/J.1524-4733.2001.40202-26.X |
0.523 |
|
| 2000 |
Lynd L, Raboud J, Guh D, Paré P, Anis A. PRS3: TRENDS IN THE USE OF β-AGONIST MEDICATIONS IN BRITISH COLUMBIA: AN ANALYSIS OF BC PHARMACARE DATA Value in Health. 3: 143-144. DOI: 10.1016/S1098-3015(11)70560-5 |
0.487 |
|
| 2000 |
Maclure M, Lynd L, Warren L, Pare P, Anis A. PMT24: “CAMOUFLAGED SAMPLING” USING BC MINISTRY OF HEALTH DATA: A METHOD OF RECRUITING SUBJECTS WHILE PRESERVING DATA PRIVACY Value in Health. 3: 109-110. DOI: 10.1016/S1098-3015(11)70474-0 |
0.509 |
|
| 2000 |
Marra C, Guh D, Fisher J, Chalmers A, Esdaile J, Anis A. PAR7: THE LONGTERM SAFETY AND EFFECTIVENESS OF CYCLOSPORINE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS (RA) Value in Health. 3: 98. DOI: 10.1016/S1098-3015(11)70444-2 |
0.538 |
|
| Show low-probability matches. |